Welcome Guest
Home > Clinical Genitourinary Cancer > Volume 4 |  Issue 4

Table of Contents

Volume 4 |  Issue 4

Publication Date: March 2006
  • Abstract Abstract
  • Full Text No Access
  • Full Text Pay-Per View
  • Full Text Full Text
  • Add to Cart Add to Cart


Editorial
Page Number of this Article in the Print Version
238-239		 The Continuing Challenge of Hormone-Refractory Prostate Cancer
Oliver Sartor
  • Abstract
  • No Access
  • Add to Cart
Meeting Highlights
Page Number of this Article in the Print Version
240-245		 Highlights from: the 2006 American Society of Clinical Oncology Prostate Cancer Symposium; San Francisco, CA; February 24-26, 2006
Sabeeha Muneer, G. Kesava Reddy, Aarati Ranganathan, Latha Shivakumar, Oliver Sartor, Vinay K. Jain
  • Abstract
  • No Access
  • Add to Cart
Mini-Review
Page Number of this Article in the Print Version
246-248		 Sorafenib: Recent Update on Activity as a Single Agent and in Combination with Interferon-α2 in Patients with Advanced-Stage Renal Cell Carcinoma
G. Kesava Reddy, Ronald M. Bukowski
  • Abstract
  • No Access
  • Add to Cart
Comprehensive Reviews
Page Number of this Article in the Print Version
249-256		 Clinical Utility of Radiolabeled Monoclonal Antibodies in Prostate Cancer
Kevin A. David, Matthew I. Milowsky, Lale Kostakoglu, Shankar Vallabhajosula, Stanley J. Goldsmith, David M. Nanus, Neil H. Bander
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
257-262		 The Role of Bisphosphonates in the Treatment of Prostate Cancer: Recommendations from an Expert Panel
Fred Saad, Celestia S. Higano, Oliver Sartor, Marc Colombel, Robin Murray, Malcolm D. Mason, Andrea Tubaro, Claude Schulman
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
263-268		 Chemotherapy for Non–Clear-Cell Renal Cell Carcinoma
Kevin A. David, Matthew I. Milowsky, David M. Nanus
  • Abstract
  • No Access
  • Add to Cart
Original Contributions
Page Number of this Article in the Print Version
269-274		 Prognostic Significance of Plasma Scatter Factor/Hepatocyte Growth Factor Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 150005/9480
Peter A. Humphrey, Susan Halabi, Joel Picus, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small, Philip W. Kantoff, for the Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, and Southwestern Oncology Group
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
275-280		 Combination Therapy of Imatinib Mesylate and Interferon-α Demonstrates Minimal Activity and Significant Toxicity in Metastatic Renal Cell Carcinoma: Results of a Single-Institution Phase II Trial
Blase N. Polite, Apurva A. Desai, Beth Manchen, Walter M. Stadler
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
281-286		 A Phase I Study of Paclitaxel/Doxorubicin/Thalidomide in Patients with Androgen-Independent Prostate Cancer
Robert J. Amato, Harmeet Sarao
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
287-292		 Weekly Docetaxel/Estramustine Phosphate in Patients with Increasing Serum Prostate- Specific Antigen Levels After Primary Treatment for Prostate Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network
John D. Hainsworth, Anthony A. Meluch, David R. Spigel, Kathleen Yost, Christina Meng, F. Anthony Greco
  • Abstract
  • No Access
  • Add to Cart
Case Report
Page Number of this Article in the Print Version
293-295		 Alkaline Phosphatase Level Increase with Initiation of Hormone Therapy for Prostate Cancer Portends Poor Prognosis with Rapid Progression to Bone Metastases: A Case Report and Review of the Literature
Michael W. Brown, Anurag K. Singh
  • Abstract
  • No Access
  • Add to Cart
Current Trials
Page Number of this Article in the Print Version
296-298		 A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Patients with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Thomas E. Hutson, Ronald M. Bukowski
  • Abstract
  • No Access
  • Add to Cart
Page Number of this Article in the Print Version
299-302		 Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design
Kathleen W. Beekman, A. Dimitrios Colevas, Kathleen Cooney, Robert DiPaola, Rodney L. Dunn, Mitchell Gross, Evan T. Keller, Kenneth J. Pienta, Charles J. Ryan, David Smith, Maha Hussain
  • Abstract
  • No Access
  • Add to Cart
Clinical Trials
Page Number of this Article in the Print Version
303		 Selected Clinical Trials in Prostate and Bladder Cancer
  • Abstract
  • No Access
  • Add to Cart